Expert perspective

know more about us

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

Biomarkers in NASH

NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.

Prof Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease.

Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston

Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.

Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.

Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting.

Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers.

Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston.